Tvardi Therapeutics, Inc. Net Income Loss

• Tvardi Therapeutics, Inc. showed an increase of +38.0% in Net Income Loss from 2024 to 2025.
• This data is from Tvardi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
• XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 14 years of available data (2012 to 2025), Tvardi Therapeutics, Inc.'s Net Income Loss has declined by 190.4%.
• Historical annual values: Fiscal year 2025: -$18.21 million | Fiscal year 2024: -$29.40 million | Fiscal year 2023: -$118.51 million | Fiscal year 2022: -$85.47 million | Fiscal year 2021: -$88.44 million | Fiscal year 2020: $8.41 million | Fiscal year 2019: -$106.37 million | Fiscal year 2018: -$74.01 million | Fiscal year 2017: -$58.13 million | Fiscal year 2016: -$57.28 million | Fiscal year 2015: -$24.69 million | Fiscal year 2014: -$17.75 million | Fiscal year 2013: -$3.96 million | Fiscal year 2012: -$6.27 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026